A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Status Completed

Clinical Trial Summary

The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.

Clinical Trial Description

This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks. ;

Study Design

Related Conditions & MeSH terms

Vitiligo

Clinical Trial Details

NCT number	NCT03468855
Study type	Interventional
Source	Aclaris Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 19, 2018
Completion date	October 16, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05298033` - Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo	Phase 2
Recruiting	`NCT05872477` - Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas	Phase 2
Terminated	`NCT04374435` - Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo	N/A
Completed	`NCT04103060` - Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo	Phase 2
Terminated	`NCT04271501` - Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions	N/A
Completed	`NCT04530344` - Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo	Phase 3
Not yet recruiting	`NCT05008887` - Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo	Phase 4
Terminated	`NCT02191748` - Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo	Phase 2/Phase 3
Completed	`NCT01382589` - Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo	Phase 2
Terminated	`NCT01262547` - A New Micrografting Technique for Vitiligo	Phase 2
Active, not recruiting	`NCT04971200` - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo	Early Phase 1
Completed	`NCT04872257` - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo	N/A
Completed	`NCT04547998` - Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions	N/A
Not yet recruiting	`NCT04039451` - Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
Not yet recruiting	`NCT03611348` - Microneedling and Latanoprost in Acrofacial Vitiligo	Phase 2/Phase 3
Recruiting	`NCT03199664` - Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo	Phase 4
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Completed	`NCT03249064` - Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2